Differentiating Pluripotent Stem Cells to Intestinal Midgut Endoderm
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating intestinal midgut endoderm cells from human pluripotent stem cells are inefficient, requiring a long time and producing a mixture of intestinal cell types with substantial contaminating mesenchyme, lacking a cellular barometer for GLP1-based diabetes treatment and being non-physiologically regulated.
Innovation Solution
A method involving specific culture media conditions and growth factors to differentiate human pluripotent stem cells into intestinal midgut endoderm cells, achieving a population where greater than 50% of cells express markers characteristic of intestinal midgut endoderm, such as CDX2, FOXA2, SOX9, PDX1, and HOXC5, without expressing SOX2, ALB, PTF1A, HOXA13, and LGR5, and maintaining a stable monolayer culture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation protocols are used to generate intestinal endoderm cells from human pluripotent stem cells, then cell production is achieved, but the process is inefficient, time-consuming, and produces a mixture of intestinal cell types with substantial contaminating mesenchyme
Solution Approach 1:
The patent modifies culture conditions by changing key parameters: adding ascorbic acid (vitamin C) to the differentiation medium, optimizing FGF2 concentration (50 ng/mL), controlling oxygen tension (5% O2), and adjusting medium composition (DMEM/F12 with specific supplements). These parameter changes accelerate differentiation efficiency while reducing contamination, resolving the contradiction between productivity and time loss.
2Quantity of substance
If conventional differentiation methods are used, then intestinal cell types are produced, but the purity is low due to substantial contaminating mesenchyme
Solution Approach 1:
The patent extracts and removes contaminating mesenchymal cells from the differentiated population through selective elimination strategies. The differentiation protocol specifically suppresses mesenchymal lineage commitment while promoting endodermal differentiation, effectively taking out the harmful contaminating component and achieving high purity intestinal endoderm cells.
Solution Approach 2:
By changing culture parameters including adding ascorbic acid, optimizing growth factor concentrations, and controlling oxygen levels, the patent shifts the differentiation trajectory to favor pure endodermal cell types while preventing mesenchymal contamination, thereby achieving high manufacturing precision.
3Quantity of substance
If current incretin-based therapies are used, then GLP1 production is achieved, but the production is not regulated by circulating blood glucose levels and thus provides non-physiologically regulated GLP production
Solution Approach 1:
The patent generates autologous patient-specific intestinal endoderm cells that can self-regulate GLP1 secretion in response to physiological stimuli. These cells inherently possess the ability to sense blood glucose levels and regulate incretin hormone secretion accordingly, providing self-service physiological regulation without requiring external control mechanisms.
Data Source
Figure 1A
Figure 1B
Figure 1C~1D
AI summary
Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed.